Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Brain metastases; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms Saci-IO TNBC
- 15 Apr 2024 Planned End Date changed from 1 Apr 2027 to 1 Apr 2029.
- 15 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2026.
- 20 Dec 2021 Planned End Date changed from 1 Jun 2026 to 1 Apr 2027.